Below are the most recent publications written about "Antigens, Differentiation, B-Lymphocyte" by people in Profiles.
-
Menssen AJ, Hudson CA, Alonzo T, Gerbing R, Pardo L, Leonti A, Cook JA, Hsu FC, Lott LL, Dai F, Fearing C, Ghirardelli K, Hylkema T, Tarlock K, Loeb KR, Kolb EA, Cooper T, Pollard J, Wells DA, Loken MR, Aplenc R, Meshinchi S, Brodersen LE. CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group. Haematologica. 2024 Oct 01; 109(10):3182-3193.
-
Djudjaj S, Lue H, Rong S, Papasotiriou M, Klinkhammer BM, Zok S, Klaener O, Braun GS, Lindenmeyer MT, Cohen CD, Bucala R, Tittel AP, Kurts C, Moeller MJ, Floege J, Ostendorf T, Bernhagen J, Boor P. Macrophage Migration Inhibitory Factor Mediates Proliferative GN via CD74. J Am Soc Nephrol. 2016 06; 27(6):1650-64.
-
Walline CC, Deffit SN, Wang N, Guindon LM, Crotzer VL, Liu J, Hollister K, Eisenlohr LC, Brutkiewicz RR, Kaplan MH, Blum JS. Virus-encoded ectopic CD74 enhances poxvirus vaccine efficacy. Immunology. 2014 Apr; 141(4):531-9.
-
Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol. 2006 Dec 15; 177(12):8730-9.
-
Imtiyaz HZ, Rosenberg S, Zhang Y, Rahman ZS, Hou YJ, Manser T, Zhang J. The Fas-associated death domain protein is required in apoptosis and TLR-induced proliferative responses in B cells. J Immunol. 2006 Jun 01; 176(11):6852-61.
-
Meyer-Siegler KL, Iczkowski KA, Vera PL. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC Cancer. 2005 Jul 06; 5:73.
-
Moll T, Nitschke L, Carroll M, Ravetch JV, Izui S. A critical role for Fc gamma RIIB in the induction of rheumatoid factors. J Immunol. 2004 Oct 01; 173(7):4724-8.
-
Mott RT, Ait-Ghezala G, Town T, Mori T, Vendrame M, Zeng J, Ehrhart J, Mullan M, Tan J. Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production. Glia. 2004 May; 46(4):369-79.
-
Tsai DE, Maillard I, Schuster SJ, Nasta SD, Porter DL, Klumpp TR, Goldenberg DM, Luger SM, Alavi A, Sharkey RM, Hartzell KB, Stadtmauer EA. Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody. Clin Lymphoma. 2003 Jun; 4(1):56-9.
-
Pushkareva MY, Wannberg SL, Janoff AS, Mayhew E. Increased cell-surface receptor expression on U-937 cells induced by 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine. Cancer Immunol Immunother. 2000 Jan; 48(10):569-78.